"10.1371_journal.pone.0134600","plos one","2015-07-30T00:00:00Z","Bong-Kook Ko; Soyoung Choi; Lei Guang Cui; Young-Ha Lee; In-Sik Hwang; Kyu-Tae Kim; Hyunbo Shim; Jong-Seo Lee","Therapeutic antibody research center, AbClon Inc., Seoul, Korea; Departments of Bioinspired Science and Life Science, Ewha Womans University, Seoul, Korea","Conceived and designed the experiments: BKK KTK HS JSL. Performed the experiments: BKK SC LGC YHL ISH. Analyzed the data: BKK KTK HS. Wrote the paper: BKK KTK HS.","BKK, SC, LGC, YHL, ISH, KTK, and JSL are all employed by AbClon Inc. and may own its stock. HS is on paid consultancy to AbClon Inc. and also owns its stock. Abclon is pursuing patents and product development on compounds that are mentioned in this paper. BKK, SC, LGC, YHL, ISH, KTK, and JSL are all currently employed by the commercial funder of this research AbClon Inc. and may own its stock. HS is currently on paid consultancy to AbClon Inc. and also owns its stock. AbClon has a registered patent in Korea (KR10-1453462, Antibodies Capable of Binding Specifically to HER2) and filed a PCT application (PCT/KR2014/004317, Antibody specifically binding to HER2) in which BKK, YHL, ISH, KTK, and JSL are listed as inventors. AbClon is also pursuing product development on the humanized, affinity-matured antibodies that are mentioned in this paper. These do not alter the authors adherence to all PLOS ONE policies on sharing data and materials.","2015","07","Bong-Kook Ko","BKK",8,TRUE,4,5,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
